Research ArticleBRAIN
An Exploratory Study of Ferumoxtran-10 Nanoparticles as a Blood-Brain Barrier Imaging Agent Targeting Phagocytic Cells in CNS Inflammatory Lesions
Sándor P. Manninger, Leslie L. Muldoon, Gary Nesbit, Tulio Murillo, Paula M. Jacobs and Edward A. Neuwelt
American Journal of Neuroradiology October 2005, 26 (9) 2290-2300;
Sándor P. Manninger
Leslie L. Muldoon
Gary Nesbit
Tulio Murillo
Paula M. Jacobs
References
- ↵Saini S, Edelman RR, Sharma P, et al. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227). AJR Am J Roentgenol 1995;164:1147–1152
- ↵Weissleder R, Elizondo G, Wittenberg J, et al. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 1990;175:494–498
- ↵Harisinghani MG, Barentsz J, Hahn PF, at al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348:2491–2499
- ↵Varallyay P, Nesbit G, Muldoon LL, et al. Comparison of two superparamagnetic viral-sized iron oxide particles Feridex and Combidex in imaging intracranial tumors. AJNR Am J Neuroradiol 2002;23:510–519
- ↵Neuwelt EA, Varallyay P, Bago A, et al. Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumors. Neuropathol Appl Neurobiol 2004;30:456–472
- ↵Neuwelt EA, Weissleder R, Nilaver G, et al. Delivery of virus-sized iron oxide particles to rodent CNS neurons. Neurosurgery 1994;34:777–784
- ↵Schmitz SA, Taupitz M, Wagner S, et al. Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles. J Magn Reson Imaging 2001;14:355–361
- ↵Kooi ME, Cappendijk VC, Cleutjens KB, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 2003;107:2453–2458
- ↵Neuwelt EA. Mechanisms of disease: the blood brain barrier. Neurosurgery 2004;54131–54142
- ↵Jung C, Jacobs P. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging 1995;13:661–674
- ↵Anzai Y, Piccoli CW, Outwater EK, et al. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study. Radiology 2003;228:777–788
- ↵McLachlan SJ, Morris MR, Lucas MA, et al. Phase I clinical evaluation of a new iron oxide MR contrast agent. J Magn Reson Imaging 1994;4:301–307
- ↵
- ↵Ge Y, Grossman RI, Udupa JK, et al. Glatiramer acetate (copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology 2000;4:813–817
- Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53–62
- Filippi M, Capra R, Campi A, et al. Triple dose of gadolinium-DTPA and delayed MRI in subjects with benign multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60:526–530
- ↵Kermode AG, Tofts PS, Thompson AJ, et al. Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology 1990;40:229–235
- ↵Silver NC, Good CD, Barker GJ, et al. Sensitivity of contrast enhanced MRI in multiple sclerosis: effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain 1997;120:1149–1161
- ↵Dousset V, Brochet B, Caille J, Petry K. Enhancement of multiple sclerosis lesions with ultra-small particle iron oxide. Proc Intl Soc Mag Reson Med 2001;9:261
- ↵Rausch M, Hiestand P., Baumann D, et al. MRI-based monitoring of inflammation and tissue damage in acute and chronic relapsing EAE. Magn Reson Med 2003;50:309–314
- ↵Floris S, Blezer ELA, Schreibelt, et al. Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study. Brain 2004;127:616–627
- ↵Arbab AS, Yocum GT, Kalish H, et al. Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood 2004;104:1217–1223
- ↵Anderson SA, Shukaliak-Quandt J, Jordan EK, et al. Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis. Ann Neurol 2004;55:654–659
- ↵Elster AD. Magnetic resonance contrast enhancement in cerebral infarction. Neuroimaging Clin N Am 1994;4:89–100
- Moseley ME, Kucharczyk J, Mintorovitch J, et al. Diffusion-weighted MR imaging of acute stroke: correlation with T2-weighted and magnetic susceptibility-enhanced MR imaging in cats. AJNR Am J Neuroradiol 1990;11:423–429
- ↵Reith W, Forsting M, Vogler H, et al. Early MR detection of experimentally induced cerebral ischemia using magnetic susceptibility contrast agents: comparison between gadopentetate dimeglumine and iron oxide particles. AJNR Am J Neuroradiol 1995;16:53–60
- ↵Hunt MA, Bago AG, Neuwelt EA. Single-dose contrast agent for intraoperative MR imaging of intrinsic brain tumors using ferumoxtran-10. AJNR Am J Neuroradiol 2005;26:1084–1088
- ↵Zhu J, Wu X, Zhang HL. Adult neural stem cell therapy: expansion in vitro, tracking in vivo and clinical transplantation. Curr Drug Targets 2005;6:97–110
- ↵Rooney WD, Telang FW, Springer-Verlag CS. Quantitative 4T determination of normal human brain vascular properties suggests CR transport across BBB. Proc Int Soc Magn Reson Med 2002;10:1314
- Rooney W, Li X, Telang F, Taylor M, et al. First pass bolus-tracking measurement of transendothelial water exchange in healthy controls. Proc Int Soc Magn Reson Med 2004;12:1390
- ↵Yankeelov TE, Rooney WD, Huang W, et al. Evidence for shutter-speed variation in CR bolus-tracking studies of human pathology. NMR Biomed 2005;18:173–185
In this issue
Advertisement
An Exploratory Study of Ferumoxtran-10 Nanoparticles as a Blood-Brain Barrier Imaging Agent Targeting Phagocytic Cells in CNS Inflammatory Lesions
Sándor P. Manninger, Leslie L. Muldoon, Gary Nesbit, Tulio Murillo, Paula M. Jacobs, Edward A. Neuwelt
American Journal of Neuroradiology Oct 2005, 26 (9) 2290-2300;
An Exploratory Study of Ferumoxtran-10 Nanoparticles as a Blood-Brain Barrier Imaging Agent Targeting Phagocytic Cells in CNS Inflammatory Lesions
Sándor P. Manninger, Leslie L. Muldoon, Gary Nesbit, Tulio Murillo, Paula M. Jacobs, Edward A. Neuwelt
American Journal of Neuroradiology Oct 2005, 26 (9) 2290-2300;
Jump to section
Related Articles
- No related articles found.
Cited By...
This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.
More in this TOC Section
Similar Articles
Advertisement